Business Wire

Resilience Software Specialist Restrata Secures Growth Investment From SEP

13.2.2025 01:01:00 CET | Business Wire | Press release

Share

Restrata, the operational resilience software and service provider to global enterprises, including some of the world’s largest energy and industrial companies, has raised investment from Scottish Equity Partners (SEP) to meet growing market demand.

The investment will support accelerated product development and AI-powered enhancements as well as expansion of existing operations in North America, Europe, and the Middle East.

Increased adoption of the London-based company’s resilienceOS platform, which helps enterprise clients protect their people, assets and operations globally, saw resilienceOS revenue surge more than 50% in 2024.

Enterprises are increasingly focused on people safety and operational resilience due to unprecedented levels of global uncertainty. In response, business leaders are seeking sophisticated technology to mitigate, manage, and respond to operational disruption while maintaining visibility and control over day-to-day operations. These threats range from localised industrial accidents and targeted physical security issues to large scale political instability and security risks, industrial and road safety, extreme weather and natural disasters, as well as organised crime or lone wolf attacks. Spend on solutions such as resilienceOS is growing rapidly, with the multi-billion-dollar market growing more than 10% each year.

The company has been serving the security and safety needs of organisations operating globally, including in high-risk locations, since 2006. Co-founders Chris St George (Chair) and Botan Osman (CEO) combined their technology, security, military and government experience to create a better way for companies to protect people and operations, powered by software.

“We built resilienceOS to solve the challenge of relying on fragmented security systems to protect people and operations,” said Botan Osman. “Security and resilience teams want to focus on what matters most and need software to act as a force multiplier. Customers, employees, and shareholders expect leaders to adopt technology that safeguards people and protects businesses.”

Chris St George added: “resilienceOS is changing the way the world’s largest companies manage safety and security. In particular, the bespoke functionality designed for the energy sector is transforming duty of care in remote, offshore and high-risk markets — ultimately protecting assets, preventing injury and saving lives.”

Customers now use resilienceOS to power global security operation centres (GSOCS) around the world, managing incidents and crises, protecting global travellers everywhere, enabling people safety, monitoring lone workers, and protecting assets.

“resilienceOS is a fully unified platform, with an open ecosystem, working from a common customer data set to more effectively respond to critical events as they happen. The unified and open nature of the platform is unique in the market, and is the key reason why some of the most complex global customers are now choosing resilienceOS,” Osman continued.

“We are delighted to be partnering with the Restrata team to help build on the business’ current momentum,” added Tim Ankers, Director at SEP. “The company has developed a strong product and international customer base. The market tailwinds are clear and Restrata’s resilienceOS product is uniquely placed to serve the increasingly sophisticated security needs of global enterprises.”

View source version on businesswire.com: https://www.businesswire.com/news/home/20250212395778/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye